Uncovering the Potential of Mineralocorticoid Receptor Antagonism to Fight Diabetic Atherosclerosis: The MAGMA Trial Explored at the NKF Spring Clinical Meetings

The MAGMA trial, sponsored by the National Heart, Lung, and Blood Institute (NHLBI), was conducted to evaluate the effects of Spironolactone, a generic drug, on diabetic atherosclerosis. Results from this study have been promising, showing activation of white cells and reduction of proteins typically associated with inflammation.

As the final results of the trail have yet to be released, they will be presented at the National Kidney Foundation’s (NKF) Spring Clinical Meetings in Austin, Texas from April 11-15. This gathering will bring together the largest multidisciplinary group of kidney care professionals in North America, making it the ideal place to hear the results of the MAGMA trial.


Spironolactone is an incredibly beneficial generic drug that should be considered for high-risk patients with diabetes and atherosclerosis.

According to Sanjay Rajagopalan, MD, FACC, FAHA, Chief of the Division of Cardiovascular Medicine and Chief Academic and Scientific Officer of UH Harrington Heart & Vascular Institute, and Herman K. Hellerstein, MD, Chair in Cardiovascular Research and a professor at the Case Western Reserve University School of Medicine, this drug has the potential to not only prevent heart failure and kidney disease progression, but also provide other positive effects.

Spironolactone could be a life-changing drug for those at risk, so it is important to explore its benefits.

NKF Spring Clinical Meetings

For three decades, nephrology professionals from across America have flocked to NKF’s Spring Clinical Meetings for an unparalleled opportunity to stay abreast of the latest developments in nephrology, connect with their peers and present their research.

This unique conference focuses on translating science into practical, impactful solutions for healthcare teams and patients alike. Whether you’re a clinician, researcher or administrator, the NKF Spring Clinical Meetings are the perfect place to learn, collaborate and make a difference.

About Kidney Disease

Do you know that more than 37 million adults in the United States are living with a silent killer—chronic kidney disease (CKD)? Sadly, 90 percent of them are unaware of it. In fact, 1 in 3 adults in the U.S. are at risk of developing this disease. Risk factors include diabetes, high blood pressure, heart disease, obesity, and a family history of kidney disease.

People of minority backgrounds such as Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at an even higher risk of kidney failure. Black or African American people are four times as likely as White people to suffer kidney failure, while Hispanics are twice as likely. It’s time to take action and get checked.

Leave a Comment